RGX-121 Gene Therapy in Patients With MPS II (Hunter Syndrome)
a study on Hunter Syndrome Mucopolysaccharidosis
Summary
- Eligibility
- for males ages 4 months to 5 years (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Dr. Paul Harmatz
Description
Summary
RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase (IDS) gene to the central nervous system. This study is a safety and dose ranging study to determine whether RGX-121 is safe and tolerated by patients with MPS II.
Official Title
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)
Details
MPS II is a rare X-linked recessive genetic disease caused by mutations in the iduronate-2-sulfatase gene (IDS). Enzyme replacement therapy (ERT) with recombinant idursulfase (ELAPRASE®) is the only approved product for the treatment of Hunter syndrome, however, ERT as currently administered does not cross the Blood Brain Barrier and is therefore unable to address the unmet need in MPS II patients with CNS (neurocognition and behavior) involvement. RGX-121 is designed to deliver a healthy gene to cells in the CNS and iduronate-2-sulfatase (I2S) where it may be secreted by transduced cells which may cross-correct non-transduced cells by taking up the functional enzyme. This is a Phase I/II, first-in-human, multicenter, open-label, single arm dose escalation study of RGX-121. Three, one time doses of RGX-121 will be studied in approximately 12 pediatric subjects who have severe MPS II. Safety will be the primary focus for the initial 24 weeks after treatment (primary study period) whereupon, subjects will continue to be assessed (safety and efficacy) for up to a total of 104 weeks following treatment with RGX-121.-121.
Keywords
Mucopolysaccharidosis Type II (MPS II) MPS II gene therapy Hunter Mucopolysaccharidosis II Mucopolysaccharidoses RGX-121 RGX-121 Dose 1 RGX-121 Dose 2 RGX-121 Dose 3
Eligibility
You can join if…
Open to males ages 4 months to 5 years
- Must meet any of the following criteria:
- Has a documented diagnosis of MPS II AND has a neurocognitive testing score ≤ 77 (Bayley or Kaufman), OR
- Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing administered between 3 to 36 months apart (Bayley or Kaufman) OR
- Has a relative clinically diagnosed with severe MPS II who has the same IDS mutation as the subject AND in the opinion of a geneticist has inherited a severe form of MPS II OR
- Has documented mutation(s) in IDS that in the opinion of a geneticist is always known to result in a neuronopathic phenotype AND in the opinion of a clinician has a severe form of MPS II
- Patient's legal guardian must be willing and able to provide written, signed informed consent.
- Is ≥4 months to <5 years of age.
You CAN'T join if...
- Has contraindications for intracisternal injection, intracerebroventricular injection, or lumbar puncture
- Has contraindications for immunosuppressive therapy
- Has neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
- Has a (cerebral) ventricular shunt that may impact the proper dosing of the subject
- Received hematopoietic stem cell transplantation
- Has had prior treatment with an AAV-based gene therapy product
- Received ELAPRASE® via intrathecal (IT) administration within 4 months of signing the ICF or experienced a serious hypersensitivity reaction to ELAPRASE®
- Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing the ICF, whichever is longer
- Has a platelet count <100,000 per microliter (µL), absolute neutrophil count <1.3 × 103/µL, or aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at screening unless the subject has a previously known history of Gilbert's syndrome
Locations
- University of California San Francisco, Benioff Children's Hospital
accepting new patients
Oakland California 94609 United States - Children's Hospital of Pittsburgh - UPMC: Program for Neurodevelopment in Rare Disorders
accepting new patients
Pittsburgh Pennsylvania 15224 United States
Lead Scientist at UCSF
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Regenxbio Inc.
- ID
- NCT03566043
- Phase
- Phase 1/2
- Study Type
- Interventional
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03566043.